U.S. pharma big copyright scrapped two experimental weight loss tablets last year—a the moment-every day capsule, lotiglipron, on account of elevated liver enzymes as well as a two times-day by day tablet, danuglipron, on account of solid Unintended effects—but CEO Albert Bourla has explained the company is determined to “Engage in and win”